OR WAIT 15 SECS
In 2010, 3M Skin and Nasal Antiseptic was launched to help address the rising concern about surgical site infections (SSI) caused by Staphylococcus aureus (S. aureus), including methicillin-resistant Staphylococcus aureus (MRSA). During the last three years, a growing body of evidence has proven the positive outcomes of utilizing this intervention as part of preoperative nasal preparation to reduce the risk of surgical site infection (SSI).
“At the time of launch, clinical studies had shown the antiseptic killed 99.5% of S. aureus in the nares in one hour and maintained that level for at least twelve hours, an important benefit for patients undergoing surgery who may be at risk for infection 1,” says DeAnn Hammer, marketing manager, 3M Infection Prevention Division. “We’ve now seen another handful of studies that continue to point to 3M Skin and Nasal Antiseptic as an important part of preoperative skin preparation to reduce the risk of SSI.”
Five distinct, third-party studies have confirmed 3M Skin and Nasal Antiseptic’s efficacy – both individually, and as part of a preoperative bundle of interventions focused on infection reduction. These studies include:
• A study by Dr. Michael Phillips, et al., of New York University published in the July 2014 issue of Infection Control and Hospital Epidemiology which concluded that skin and nasal antiseptic may be considered as an alternative to mupirocin in a multifaceted approach to reduce SSI.2
• Highland Hospital presented their study in a poster at the 2014 APIC National Conference that showed the overall rate of SSI decreased significantly following intranasal antisepsis p=0.03 with 3M Skin and Nasal Antiseptic. A statistically significant reduction in hip arthoplasty SSI was also achieved (p=0.045).3
• A poster presented at the 2013 APIC National Conference by Marcia Waibel, MBA, MT(ASCP), CIC of Riverside Methodist Hospital showed that patients receiving nasal antiseptic avoided $62,302 in readmission costs.4
• Dr. Jette Hogenmiller presented a poster at the APIC National Conference in 2011 reporting a 100% reduction in SSI on Orthopedic Total Hip and Knee Arthoplasty patients following implementation of a ‘best practices’ pre-operatory checklist, which included use of 3M Skin and Nasal Antiseptic.5
• In an in vitro study presented at ASM in May 2014, the Mayo Clinic determined that 3M Skin and Nasal Antiseptic is effective in killing mupirocin non-susceptible MRSA and vancomycin-intermediate MRSA.6
Staphylococcus aureus is the leading cause of surgical site infections7 with approximately 80 percent of S. aureus infections caused by the patient’s own nasal flora.8 As the only product designed to work within the preoperative process to quickly and effectively reduce S. aureus colonization in the nares1, healthcare providers can be confident their patients are entering surgery with a reduced risk of infection.
“In addition to clinical efficacy, 3M Skin and Nasal Antiseptic also solves the patient compliance challenge – it’s a quick 2-minute application, is effective in one hour, and persists for 12 hours1,” says Hammer. “Additionally, the antiseptic formulation won’t lead to resistance or impact antibiotic stewardship9.”
3M Skin and Nasal Antiseptic is designed to be used in the preoperative process. The solution consists of film-forming materials that enable the active ingredient to remain in the nares and efficiently coat and adhere to the nares where bacteria reside. This is especially important because the unique physiology of the nose presents many challenges. The nose works continuously to clear foreign particles and microorganisms making it difficult for antimicrobials to reach and kill bacteria.
3M Skin and Nasal Antiseptic is packaged in an easy-to-open 4 mL bottle with sterile swabs. The swabs are designed to fit comfortably into nostrils while providing good coverage of the nares with minimal dripping or running.
Source: 3M Infection Prevention Division
1. 3M Study-05-011100.
2. Phillips M., et al. Preventing Surgical Site Infections: A Randomized, Open-Label Trial of Nasal Mupirocin
Ointment and Nasal Povidone-Iodine Solution. Infect Control Hosp Epidemiol 2014;35(7):826-32
3. Brown, L., et al. (2014, June) The Effect of Universal Intranasal Povidone Iodine Antisepsis on Total Joint Replacement Surgical Site Infections. Poster presented at the APIC National Conference, Anaheim, CA.
4. Waibel, M. (2013, June) Revisiting Process Improvement for Total Joint Arthroplasty Surgical Site Infections. Poster presented at the APIC National Conference, Ft. Lauderdale, FL.
5. Hogenmiller, J., et al. (2011, June) Preventing Orthopedic Total Joint Replacement Surgical Site Infections through a Comprehensive Best Practice Bundle/Checklist. Poster presented at the APIC National Conference, Baltimore, MD.
6. Karau, M., et al. 3M™ Skin and Nasal Antiseptic and 3M™ DuraPrep™ Surgical Solution Bactericidal Activity Against Methicillin-Resistant Staphylococcus Aureus Poster presented at American Society for Microbiology May 2014.
7. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011.
8. Wertheim, HFL, et al. Risk and Outcome of Nosocomial Staphylococcus aureus Bacteraemia in Nasal Carriers versus Non-carriers. The Lancet 2004;364: 703-705.
9. 3M Study-05-011322.